Richter, Mithra sign deal to sell new oral contraceptive in Latin America
Image by LaMography/Moni Lazar
Hungarian pharmaceutical company Gedeon Richter and Estetra, a unit of Belgian peer Mithra, on Wednesday said they signed a license and supply agreement for the commercialization of a new oral contraceptive, state news wire MTI reports.
The oral contraceptive contains 15 mg estetrol (E4), a unique native estrogen, and 3 mg drospirenone.
Under the terms of the agreement Richter will distribute Mithra’s product in Mexico, Chile, Colombia, Peru and Ecuador, with an option for other markets except for Brazil and Argentina.
Richter will make an upfront payment to be followed by milestone payments contingent on the progress of the regulatory process of the product and on sales after the product launch.
Richter announced a partnership with Mithra in September 2018 to sell the oral contraceptive. Under that agreement, Richter will sell the drug in Europe, Russia and other CIS countries under a different brand name.
Mithra sells the contraceptive under the Estelle brand.
Oral contraceptives are Richter's top-selling products.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.